Table 3

Univariate logistic regression for patients undergoing endocrine treatment without ovarian ablation (group 1 and group 2: n=2224) versus with ovarian ablation (group 3 and group 4: n=516)

LevelsOR95% CI lower bounds95% CI upper boundsp value
Age at diagnosisAs one year increase0.9750.9610.990 0.001
Year of diagnosis2011 vs 20100.9710.7001.347 <0.001
2012 vs 20101.1080.8001.535
2013 vs 20101.2050.8851.641
2014 vs 20101.7131.2712.308
Family history (77 unknown)Yes vs no1.1980.9851.4580.071
Live childrenYes vs no1.1310.9091.4080.271
HistologyLobular no ductal vs ductal no lobular1.2020.8841.636 0.019
Lobular and ductal vs ductal no lobular0.9830.6631.457
Inflammatory vs ductal no lobular1.4200.3835.268
Other vs ductal no lobular0.2340.0950.579
Grade (219 unknown)G2 vs G12.9881.6745.331 <0.001
G3 vs G13.4071.9545.940
LN pos exact (3 unknown)Yes vs no1.8941.5602.300 <0.001
Stage (210 unknown)II vs I1.4771.1761.856 <0.001
III vs I2.8592.1533.798
ChemotherapyYes vs no1.5161.2321.865 <0.001
HER-2 targetedTrastuzumab vs none0.8920.6551.214 <0.001
Trastuzumab+other vs none2.2761.5023.449
  • The OR is modeled for ovarian suppression (OS)=yes. OR>1 means more likely to get OS; OR<1 less likely to get OS. Unknown=number of patients in analysis who did not have documentation for this variable.

  • Bold p values represent p values of significance.

  • HER-2, human epidermal growth factor receptor 2; LN, lymph node; OS, ovarian suppression.